5 research outputs found
Temporal clinical and laboratory response to interleukin-6 receptor blockade with tocilizumab in 89 hospitalized patients with covid-19 pneumonia
Background: Pandemic COVID-19 pneumonia due to SARS-2 is an important cause of morbidi-ty and mortality. Emerging evidence links poor outcomes to an inflammatory cytokine storm. Methods: We treated 89 hospitalized patients with COVID-19 pneumonia and heightened systemic inflammation (elevated serum C reactive protein and interleukin-6 levels) with an infusion of tocilizumab (TCZ), a human monoclonal IgG1 antibody to the interleukin-6 receptor. Results: Clinical and laboratory evidence of improvement was evident when baseline and 1-2-day post-infusion indices were compared. Among the 72 patients receiving supplemental oxygen without mechanical ventilation, severity of condition on the NEWS2 scale scores fell from 5 to 2 (
Uncontrolled course of respiratory allergic diseases in pregnant women
A.A. Paschenko1, Yu.E. Dobrokhotova1, D.S. Fomina2,3, M.G. Pashchenko4
1Pirogov Russian National Research Medical University, Moscow, Russian Federation
2City Clinical Hospital No. 52, Moscow, Russian Federation
3I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation
4P.V. Mandryka Central Military Clinical Hospital, Moscow, Russian Federation
The article presents the analysis of literature data on the pathogenesis, course and pharmacotherapy in pregnancy during respiratory allergic diseases. The article also considers the systematized ARIA recommendations (Updated 2020) on the diagnosis and pharmacotherapy of allergic rhinitis (AR) in pregnancy, differential diagnosis concerning nasal breathing disorders of atopic and non-atopic etiology during gestation, and the developed therapeutic methods for the patient management (in particular, pregnant women) with an allergic phenotype (a combination of asthma with allergic rhinitis and/or atopic dermatitis). The association between the uncontrolled course of allergic rhinitis in pregnant women and the risk of the bronchial asthma onset has been proven. Of utmost importance, for improving perinatal outcomes is the optimization of therapy and symptom control of allergic diseases during pregnancy in the interdisciplinary practice of an obstetrician-g ynecologist and allergist/immunologist. AR in pregnancy should be differentiated from the most common form of nasal breathing disorders in pregnant women β vasomotor rhinitis. Severe uncontrolled vasomotor rhinitis in pregnant women, as an individual nosological form, can worsen the existing AR and bronchial asthma course. The authors present a mathod for the AR step therapy based on pharmacological characteristics and safety profile of drugs in pregnancy.
Keywords: allergic rhinitis, bronchial asthma, pregnancy, vasomotor rhinitis of pregnant women, pharmacotherapy, obstetric complications.
For citation: Paschenko A.A., Dobrokhotova Yu.E., Fomina D.S., Pashchenko M.G. Uncontrolled course of respiratory allergic diseases in pregnant women. Russian Journal of Woman and Child Health. 2022;5(2):122β128 (in Russ.). DOI: 10.32364/2618-8430-2022-5-2-122-128.
</p
Direct analysis of water-soluble soil organic matter in the aqueous phase using fourier-transform infrared spectroscopy
ΠΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΡΡΠ°Π²Π½Π΅Π½ΠΈΠ΅ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² ΡΠ΅ΡΠ»ΠΈΠ·ΡΠΌΠ°Π±, ΠΌΠ΅ΠΏΠΎΠ»ΠΈΠ·ΡΠΌΠ°Π± ΠΈ Π±Π΅Π½ΡΠ°Π»ΠΈΠ·ΡΠΌΠ°Π± Π² ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΡΠΆΠ΅Π»ΠΎΠΉ ΡΠΎΠ·ΠΈΠ½ΠΎΡΠΈΠ»ΡΠ½ΠΎΠΉ Π±ΡΠΎΠ½Ρ ΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π°ΡΡΠΌΡ
During last few years, the approaches to the management of patients with severe asthma have been revised. Monoclonal antibodies (MABs), inhibitors of interleukin-5 (reslizumab, mepolizumab, benralizumab) have been recently introduced for the treatment of severe eosinophilic asthma. The mentioned drugs were approved in Russia and included into the list of Vitally Essential Drugs. Aim. The aim of this study was to compare the clinical and economic consequences of the use of biological agents that antagonize IL-5 in the treatment of severe eosinophilic asthma in adults. Materials and methods. Two methods of clinical and economic research were used: assessment of the cost-effectiveness ratio and analysis of the budget impact. The effectiveness of the drugs was assessed using indirect comparison; special attention was paid to comparability of the patient groups in the studies chosen for such an assessment. Two approaches were used for calculation of the cost of therapy for severe asthma: using DRGs (applicable to most regions of Russia), and without the use of DRGs, which is relevant only for few Russian regions. results. Basing on the data obtained from a budget impact study without the use of DRG, it was shown that reslizumab was dominating for patients with body mass of up to 70 kg, while for the patients with body mass of 70 to 110 kg, mepolizumab was dominating, while utilization of reslizumab appeared to be somewhat more expensive. In the group of patients with body mass over 110 kg, mepolizumab also was dominating. The calculation of the cost-effectiveness ratio (CER) showed that reslizumab appeared to be dominating over two other MABs, The results of the study using the DRG demonstrated that the cost of an annual course of benralizumab in most cases in Russia would exceed the amount that can be compensated by Territorial Funds for Mandatory Medical Insurance to a healthcare institution for therapy of bronchial asthma in one adult patient with genetically engineered drugs. Therefore, further comparisons were made for reslizumab and mepolizumab only. Analysis of the impact on the budget demonstrated that treatment with reslizumab and mepolizumab would represent a similar burden for the budget. When applying cost-effectiveness analysis, reslizumab was more cost-effective than mepolizumab (regardless of patient body mass). conclusion. Thus, the results of the clinical and economic study suggested that, basing on the cost-effectiveness analysis, reslizumab appeared to be the dominant IL-5 antagonist (regardless of body mass if DRG approach was used and in patients with body mass up to 110 kg, if such an approach was not used). Basing on budget impact analysis, calculations without use of DRG approach showed superiority of reslizumab over mepolizumab and benralizumab for the patients with body mass up to 70 kg and the DRG-based approach showed equal burden for the budget for reslizumab and mepolizumab for the patients with any body mass. Β© 2020 Consilium Medikum. All rights reserved.Π ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΠ΅ Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΎ Π»Π΅Ρ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΡΠ°ΡΠΌΠ°ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΠΎΠ΄Ρ
ΠΎΠ΄Ρ ΠΊ Π²Π΅Π΄Π΅Π½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΡΠΆΠ΅Π»ΠΎΠΉ Π±ΡΠΎΠ½Ρ
ΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π°ΡΡΠΌΠΎΠΉ (Π’Π) ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ ΠΏΠ΅ΡΠ΅ΡΠΌΠΎΡΡΠ΅Π½Ρ. ΠΠ»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ ΡΡΠΆΠ΅Π»ΠΎΠΉ ΡΠΎΠ·ΠΈΠ½ΠΎΡΠΈΠ»ΡΠ½ΠΎΠΉ Π°ΡΡΠΌΡ ΠΏΡΠ΅Π΄Π»ΠΎΠΆΠ΅Π½Ρ ΠΌΠΎΠ½ΠΎΠΊΠ»ΠΎΠ½Π°Π»ΡΠ½ΡΠ΅ Π°Π½ΡΠΈΡΠ΅Π»Π° β ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΡ ΠΈΠ½ΡΠ΅ΡΠ»Π΅ΠΉΠΊΠΈΠ½Π°-5 (IL-5): ΡΠ΅ΡΠ»ΠΈΠ·ΡΠΌΠ°Π±, ΠΌΠ΅ΠΏΠΎΠ»ΠΈΠ·ΡΠΌΠ°Π±, Π±Π΅Π½ΡΠ°Π»ΠΈΠ·ΡΠΌΠ°Π±. ΠΠ΅ΡΠ΅ΡΠΈΡΠ»Π΅Π½Π½ΡΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ Π·Π°ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π½Ρ Π² Π ΠΎΡΡΠΈΠΈ ΠΈ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ Π² ΡΠΏΠΈΡΠΎΠΊ ΠΆΠΈΠ·Π½Π΅Π½Π½ΠΎ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΡΡ
ΠΈ Π²Π°ΠΆΠ½Π΅ΠΉΡΠΈΡ
Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ².
Π¦Π΅Π»Ρ. Π‘ΡΠ°Π²Π½Π΅Π½ΠΈΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈ ΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΠΎΡΠ»Π΅Π΄ΡΡΠ²ΠΈΠΉ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ², Π°Π½ΡΠ°Π³ΠΎΠ½ΠΈΡΡΠΎΠ² IL-5 ΠΏΡΠΈ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΡΠΆΠ΅Π»ΠΎΠΉ ΡΠΎΠ·ΠΈΠ½ΠΎΡΠΈΠ»ΡΠ½ΠΎΠΉ Π°ΡΡΠΌΡ Ρ Π²Π·ΡΠΎΡΠ»ΡΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ².
ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½Ρ 2 ΠΌΠ΅ΡΠΎΠ΄Π° ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ: Π°Π½Π°Π»ΠΈΠ· Β«Π·Π°ΡΡΠ°ΡΡβΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΒ» ΠΈ Π°Π½Π°Π»ΠΈΠ· Π²Π»ΠΈΡΠ½ΠΈΡ Π½Π° Π±ΡΠ΄ΠΆΠ΅Ρ. ΠΡΠΈ ΡΡΠ°Π²Π½Π΅Π½ΠΈΠΈ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Ρ ΠΏΠΎΠΌΠΎΡΡΡ Π½Π΅ΠΏΡΡΠΌΠΎΠ³ΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ ΠΎΡΠΎΠ±ΠΎΠ΅ Π²Π½ΠΈΠΌΠ°Π½ΠΈΠ΅ ΡΠ΄Π΅Π»Π΅Π½ΠΎ ΡΠΎΠΏΠΎΡΡΠ°Π²ΠΈΠΌΠΎΡΡΠΈ Π³ΡΡΠΏΠΏ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΏΠΎΠ»ΡΡΠ°Π²ΡΠΈΡ
ΡΠ΅ΡΠ°ΠΏΠΈΡ ΡΡΠ°Π²Π½ΠΈΠ²Π°Π΅ΠΌΡΠΌΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°ΠΌΠΈ. ΠΡΠΈ ΡΠ°ΡΡΠ΅ΡΠ΅ ΡΡΠΎΠΈΠΌΠΎΡΡΠΈ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΡΠΆΠ΅Π»ΠΎΠΉ Π±ΡΠΎΠ½Ρ
ΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π°ΡΡΠΌΡ (Π’Π) ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½Ρ Π΄Π²Π° ΠΏΠΎΠ΄Ρ
ΠΎΠ΄Π°: Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π³ΡΡΠΏΠΏ (ΠΠ‘Π), ΡΡΠΎ ΠΏΡΠΈΠΌΠ΅Π½ΠΈΠΌΠΎ ΠΊ Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Ρ ΡΠ΅Π³ΠΈΠΎΠ½ΠΎΠ² Π ΠΎΡΡΠΈΠΈ, ΠΈ Π±Π΅Π· ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ ΠΠ‘Π, ΡΡΠΎ ΡΠ΅Π»Π΅Π²Π°Π½ΡΠ½ΠΎ Π»ΠΈΡΡ Π΄Π»Ρ ΠΌΠ°Π»ΠΎΠ³ΠΎ ΡΠΈΡΠ»Π° ΡΠ΅Π³ΠΈΠΎΠ½ΠΎΠ² Π ΠΎΡΡΠΈΠΈ.
Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠ° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π±Π΅Π· ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ ΠΠ‘Π Π΄Π»Ρ ΡΠ°ΡΡΠ΅ΡΠ° ΡΡΠΎΠΈΠΌΠΎΡΡΠΈ Π·Π°ΠΊΠΎΠ½ΡΠ΅Π½Π½ΠΎΠ³ΠΎ ΡΠ»ΡΡΠ°Ρ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ Ρ ΡΠΎΡΠΊΠΈ Π·ΡΠ΅Π½ΠΈΡ Π²Π»ΠΈΡΠ½ΠΈΡ Π½Π° Π±ΡΠ΄ΠΆΠ΅Ρ Π΄ΠΎΠΌΠΈΠ½ΠΈΡΡΡΡΠΈΠΌ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠΌ Π΄Π»Ρ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΌΠ°ΡΡΠΎΠΉ ΡΠ΅Π»Π° ΠΌΠ΅Π½Π΅Π΅ 70 ΠΊΠ³ ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΠ΅ΡΠ»ΠΈΠ·ΡΠΌΠ°Π±, ΠΎΡ 70 Π΄ΠΎ 110 ΠΊΠ³ β ΠΌΠ΅ΠΏΠΎΠ»ΠΈΠ·ΡΠΌΠ°Π±, ΠΈ Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΎ Π±ΠΎΠ»Π΅Π΅ Π·Π°ΡΡΠ°ΡΠ½ΡΠΌ ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΠ΅ΡΠ»ΠΈΠ·ΡΠΌΠ°Π±, Π² Π³ΡΡΠΏΠΏΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΌΠ°ΡΡΠΎΠΉ ΡΠ΅Π»Π° Π±ΠΎΠ»Π΅Π΅ 110 ΠΊΠ³ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅Π½ ΡΠ°ΠΊΠΆΠ΅ ΠΌΠ΅ΠΏΠΎΠ»ΠΈΠ·ΡΠΌΠ°Π±. ΠΡΡΠΈΡΠ»Π΅Π½ΠΈΠ΅ ΠΊΠΎΡΡΡΠΈΡΠΈΠ΅Π½ΡΠ° Β«Π·Π°ΡΡΠ°ΡΡβΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΒ» ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΎ, ΡΡΠΎ Π΄Π°Π½Π½ΡΠΉ ΠΊΠΎΡΡΡΠΈΡΠΈΠ΅Π½Ρ Π΄Π»Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΌΠ°ΡΡΠΎΠΉ Π΄ΠΎ 110 ΠΊΠ³ Π½Π°ΠΈΠΌΠ΅Π½ΡΡΠΈΠΉ Π΄Π»Ρ ΡΠ΅ΡΠ»ΠΈΠ·ΡΠΌΠ°Π±Π°, ΡΡΠΎ ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΠ΅Ρ ΠΎ Π΄ΠΎΠΌΠΈΠ½ΠΈΡΠΎΠ²Π°Π½ΠΈΠΈ ΡΡΠΎΠ³ΠΎ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Π΄Π°Π½Π½ΠΎΠΉ Π³ΡΡΠΏΠΏΡ. ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΠ‘Π Π΄Π»Ρ ΡΠ°ΡΡΠ΅ΡΠ° ΡΡΠΎΠΈΠΌΠΎΡΡΠΈ Π·Π°ΠΊΠΎΠ½ΡΠ΅Π½Π½ΠΎΠ³ΠΎ ΡΠ»ΡΡΠ°Ρ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΈ, ΡΡΠΎ ΡΡΠΎΠΈΠΌΠΎΡΡΡ Π³ΠΎΠ΄ΠΎΠ²ΠΎΠ³ΠΎ ΠΊΡΡΡΠ° Π±Π΅Π½ΡΠ°Π»ΠΈΠ·ΡΠΌΠ°Π±Π° Π² Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²Π΅ ΡΠ΅Π³ΠΈΠΎΠ½ΠΎΠ² Π ΠΎΡΡΠΈΠΈ Π±ΡΠ΄Π΅Ρ ΠΏΡΠ΅Π²ΡΡΠ°ΡΡ ΡΡΠΌΠΌΡ, ΠΊΠΎΡΠΎΡΠ°Ρ ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ ΠΊΠΎΠΌΠΏΠ΅Π½ΡΠΈΡΠΎΠ²Π°Π½Π° ΡΠ΅ΡΡΠΈΡΠΎΡΠΈΠ°Π»ΡΠ½ΡΠΌ ΡΠΎΠ½Π΄ΠΎΠΌ ΠΎΠ±ΡΠ·Π°ΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠ³ΠΎ ΡΡΡΠ°Ρ
ΠΎΠ²Π°Π½ΠΈΡ Π½Π° ΡΠ΅ΡΠ°ΠΏΠΈΡ Π±ΡΠΎΠ½Ρ
ΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π°ΡΡΠΌΡ Π³Π΅Π½Π½ΠΎ-ΠΈΠ½ΠΆΠ΅Π½Π΅ΡΠ½ΡΠΌΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°ΠΌΠΈ Ρ ΠΎΠ΄Π½ΠΎΠ³ΠΎ Π±ΠΎΠ»ΡΠ½ΠΎΠ³ΠΎ. Π ΡΠ²ΡΠ·ΠΈ Ρ ΡΡΠΈΠΌ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠ΅Π΅ ΡΡΠ°Π²Π½Π΅Π½ΠΈΠ΅ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΎΡΡ Π΄Π»Ρ ΡΠ΅ΡΠ»ΠΈΠ·ΡΠΌΠ°Π±Π° ΠΈ ΠΌΠ΅ΠΏΠΎΠ»ΠΈΠ·ΡΠΌΠ°Π±Π°. ΠΠ½Π°Π»ΠΈΠ· Π²Π»ΠΈΡΠ½ΠΈΡ Π½Π° Π±ΡΠ΄ΠΆΠ΅Ρ ΠΏΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°Π» ΡΠ°Π²Π½ΡΠ΅ Π·Π°ΡΡΠ°ΡΡ Π±ΡΠ΄ΠΆΠ΅ΡΠ° Π½Π° ΡΠ΅ΡΠ°ΠΏΠΈΡ ΡΠ΅ΡΠ»ΠΈΠ·ΡΠΌΠ°Π±ΠΎΠΌ ΠΈ ΠΌΠ΅ΠΏΠΎΠ»ΠΈΠ·ΡΠΌΠ°Π±ΠΎΠΌ. ΠΡΠΈ ΡΡΠΎΠΌ Π°Π½Π°Π»ΠΈΠ· Β«Π·Π°ΡΡΠ°ΡΡβΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΒ» ΠΏΠΎΠΊΠ°Π·Π°Π» Π±ΠΎΠ»Π΅Π΅ Π²ΡΡΠΎΠΊΡΡ ΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΡΠ΅ΡΠ»ΠΈΠ·ΡΠΌΠ°Π±Π° ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΌΠ΅ΠΏΠΎΠ»ΠΈΠ·ΡΠΌΠ°Π±ΠΎΠΌ (Π½Π΅Π·Π°Π²ΠΈΡΠΈΠΌΠΎ ΠΎΡ ΠΌΠ°ΡΡΡ ΡΠ΅Π»Π° ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°).
ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡ ΠΏΡΠ΅Π΄ΠΏΠΎΠ»ΠΎΠΆΠΈΡΡ, ΡΡΠΎ Π½Π° ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠΈ Π°Π½Π°Π»ΠΈΠ·Π° Β«Π·Π°ΡΡΠ°ΡΡβΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡΒ» Π΄ΠΎΠΌΠΈΠ½ΠΈΡΡΡΡΠΈΠΌ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠΌ-Π°Π½ΡΠ°Π³ΠΎΠ½ΠΈΡΡΠΎΠΌ IL-5 ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΠ΅ΡΠ»ΠΈΠ·ΡΠΌΠ°Π± [Π΄Π»Ρ Π²ΡΠ΅Ρ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΡΠΆΠ΅Π»ΠΎΠΉ ΡΠΎΠ·ΠΈΠ½ΠΎΡΠΈΠ»ΡΠ½ΠΎΠΉ Π°ΡΡΠΌΠΎΠΉ (Π½Π΅Π·Π°Π²ΠΈΡΠΈΠΌΠΎ ΠΎΡ ΠΌΠ°ΡΡΡ ΡΠ΅Π»Π°) ΠΏΡΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠΈ ΠΠ‘Π ΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΌΠ°ΡΡΠΎΠΉ ΡΠ΅Π»Π° Π΄ΠΎ 110 ΠΊΠ³ Π±Π΅Π· ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ ΠΠ‘Π]. ΠΠ½Π°Π»ΠΈΠ· Π²Π»ΠΈΡΠ½ΠΈΡ Π½Π° Π±ΡΠ΄ΠΆΠ΅Ρ Π΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΡΠ΅Ρ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π²ΡΡΠΎΠΊΡΡ ΡΠΊΠΎΠ½ΠΎΠΌΠΈΡΠ½ΠΎΡΡΡ ΡΠ΅ΡΠ»ΠΈΠ·ΡΠΌΠ°Π±Π° Π΄Π»Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΌΠ°ΡΡΠΎΠΉ ΡΠ΅Π»Π° Π΄ΠΎ 70 ΠΊΠ³ (Π±Π΅Π· ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΠ‘Π), ΠΏΡΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠΈ ΠΠ‘Π Π·Π°ΡΡΠ°ΡΡ Π±ΡΠ΄ΠΆΠ΅ΡΠ° Π΄Π»Ρ ΠΌΠ΅ΠΏΠΎΠ»ΠΈΠ·ΡΠΌΠ°Π±Π° ΠΈ ΡΠ΅ΡΠ»ΠΈΠ·ΡΠΌΠ°Π±Π° ΡΠ°Π²Π½Ρ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π»ΡΠ±ΠΎΠΉ ΠΌΠ°ΡΡΠΎΠΉ ΡΠ΅Π»Π°